Intraperitoneal Maintenance Therapy

Intraperitoneal maintenance therapy is the ongoing delivery of chemotherapy directly into the abdominal cavity (the peritoneum) after initial treatment for peritoneal mesothelioma or other abdominal cancers. It is used to keep the disease under control after surgery and/or first-line chemotherapy by bathing the lining of the abdomen in drug at high local concentration. Treatments are typically given on a repeating schedule through a surgically placed port or catheter.

Origin

The approach grew out of decades of intraperitoneal chemotherapy research in ovarian and gastrointestinal cancers, and was adapted for peritoneal mesothelioma in the 1990s and 2000s alongside cytoreductive surgery and HIPEC (heated intraperitoneal chemotherapy). The word "peritoneum" comes from the Greek peritonaion, meaning "stretched around," describing the membrane lining the abdomen.

Significance in Asbestos Context

For patients with peritoneal mesothelioma, a cancer of the abdominal lining caused by asbestos exposure, intraperitoneal maintenance therapy can extend the disease-free interval after cytoreductive surgery and HIPEC. Because the drug is delivered directly to the area where mesothelioma tends to recur, much higher concentrations reach the tumor than would be possible with IV chemotherapy alone, often with fewer body-wide side effects. Patients should ask their oncologist whether they are candidates, what drugs will be used (commonly cisplatin, pemetrexed, or paclitaxel), how the port will be placed and maintained, and how response will be monitored. Records of these treatments (including operative notes for port placement, infusion logs, and imaging) are important parts of the medical record that document both the diagnosis and the aggressive treatment course, which can be relevant to damages in a legal claim.

Example Sentence

After her cytoreductive surgery and HIPEC for peritoneal mesothelioma, her oncologist recommended several months of intraperitoneal maintenance therapy through an implanted abdominal port to reduce the chance of recurrence.

Related Terms

Peritoneal Mesothelioma, HIPEC, Cytoreductive Surgery, Pemetrexed, Cisplatin, Peritoneum

Notes

• Ask your oncologist whether you are a candidate, which drugs will be used, how many cycles are planned, and what objective measures (imaging, tumor markers, laparoscopy) will be used to judge response.
• Keep all operative reports for port or catheter placement, infusion records, and pathology reports. These document the diagnosis and treatment intensity and are important for both ongoing care and any legal claim.
• Watch for and promptly report signs of port infection, catheter blockage, abdominal pain, fever, or bowel changes; intraperitoneal access carries specific risks that differ from standard IV chemotherapy.
• Treatment is typically delivered at specialized centers experienced in peritoneal surface malignancies; consider seeking care or a second opinion at such a center if you are not already being treated there.